PARAMEDICS, RESEARCHERS AND WORKFORCE ANALYSTS GATHER LANDMARK PARAMEDICINE WORKFORCE DATASET Inaugural report into Australasian Paramedicine Workforce Survey report to aid workforce planning
INTERVIEWS
Dr Liz Thyer, Associate Professor in Paramedicine
School of Health Sciences, Western Sydney University &
Chief Investigator Australasian Paramedicine Workforce Survey Report 2023-2024
Alecka Miles, Community Paramedic, Dianella Family Medical Centre (WA)
Lecturer Edith Cowan University &
PhD Student Western Sydney University
John Bruning, Chief Executive Officer
Australasian College of Paramedicine
SEGMENT
Filmed in Campbelltown (NSW), Perth & Sydney | December 2024
In a milestone for paramedicine, the Australasian College of Paramedicine earlier this year released the first report of a landmark three-year study identifying and exploring trends that affect the Australasian paramedicine workforce.
The inaugural Australasian Paramedicine Workforce Survey report 2023-24 explores the demographic, career trajectory, work motivations and conditions for those working in clinical, management and educational capacities within the paramedicine workforce of Australia and Aotearoa New Zealand.
The survey findings reveal new insights into the current and future state of the paramedicine workforce across Australia and Aotearoa New Zealand and provide governments and decision-makers with crucial knowledge and evidence to better inform workforce planning.
In 2022, the College commissioned Associate Professor Liz Thyer, from Western Sydney University (WSU), as Chief Investigator to lead a team of sixteen academics and researchers from WSU, Edith Cowan University (ECU) and Auckland University of Technology (AUT). Alecka Miles (ECU) and Dr Graham Howie (AUT) led the teams from their respective universities.
Australian Health Journal spoke with Associate Professor Liz Thyer, Alecka Miles and John Bruning, Chief Executive Officer for the Australasian College of Paramedicine about the survey and the inaugural report.
Assoc Prof Liz Thyer said: “Our team includes paramedics, researchers and workforce analysts enabling us to develop a survey that gets to the core of the paramedic profession. These insights can then be used to make a better, well-supported workforce for current paramedics and those studying to enter the profession.”
The data contained in this report will assist the College, and the broader paramedicine healthcare sector, in workforce planning. As health reform across Australasia looks to more broadly engage paramedics in multidisciplinary team-based models, the survey findings aim to support all employers of paramedics in better understanding the needs of their workforce, ultimately enhancing the quality of care provided to communities across Australia and Aotearoa New Zealand.
Also captured in this segment from the College’s ACPIC conference in Sydney in September 2024 include Lucy Oatley ASM (Conference Master of Ceremonies), Intensive Care Flight Paramedic and Jemma Altmeier, Advocacy and Government Relations Manager, Australasian College of Paramedicine.
-
Medicinal cannabis in Australia Update
According to the Australian Journal of General Practice, published by the Royal Australian College of General Practitioners, more than 130,000 medicinal cannabis approvals have been issued in Australia to date, mostly by general practitioners, with approximately 65% of these to treat chronic non-cancer pain. Despite robust supportive data from animal models, current clinical trial evidence for THC and CBD efficacy in chronic pain is incomplete. In their prescribing decisions, doctors must balance patient demand and curiosity with caution regarding potential risks and limited efficacy (Source: https://www1.racgp.org.au/ajgp/2021/october/medicinal-cannabis)
Australian Health Journal met with 3 speakers at the recent @arcsaustralia ARCS22 Conference providing an update on medicinal cannabis. The discussion with the speakers now centres on affordability and access.
-
Australian Healthcare and Hospitals Association (AHHA) Blueprint Refresh Roundtable
AHHA’s Blueprint Refresh Roundtable brings together AHHA members and other Australian health leaders to evaluate the progress made to date against Healthy people, healthy systems and to tease out key policy issues that need to be addressed in order to implement outcomes-focused, value-based care in Australia.
-
ICTD: Why negative results in clinical trials matter
To mark International Clinical Trials Day 2026, Australian Health Journal commences a 4 part special series leaving up to 20th May. Through conversations with leading researchers, clinicians and trial organisations, the series highlights achievements in the year that was for clinical trials.
Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.Negative results in a clinical trial can be extremely valuable — both scientifically and ethically. A “negative result” usually means the treatment being tested did not work better than the standard treatment, placebo, or expected outcome.
